Atezolizumab: all 521 studies that test it

Page 4 of 6. Open to participants first (107), then studies with results posted, then the rest; newest registration first within each.

• Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/AmplificationWithdrawnNCT05510427Phase 1
• Evaluating Novel Therapies in ctDNA Positive GI CancersActive, not recruitingNCT05482516Phase 3
• A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the LungActive, not recruitingNCT05470595Phase 2
• Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerActive, not recruitingNCT05425940Phase 3
• Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 TrialActive, not recruitingNCT05411081Phase 2
• Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial CarcinomaActive, not recruitingNCT05394337Phase 1/2
• Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint InhibitorsActive, not recruitingNCT05334329Phase 1
• Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular CarcinomaWithdrawnNCT05327738Phase 2
• Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma PatientsActive, not recruitingNCT05300282Phase 1/2
• Thiopurine Enhanced Mutations for PD-1/Ligand-1 EfficacyCompletedNCT05276284Phase 1/2
• Atezolizumab Plus CArboplatin Plus Nab-paclitaxelActive, not recruitingNCT05266937Phase 2
• A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).Active, not recruitingNCT05240131Phase 1/2
• SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
• Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard TherapyTerminatedNCT05180006Phase 2
• Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/RearrangementsActive, not recruitingNCT05174650Phase 2
• Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT05168618Phase 2
• A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard TreatmentsActive, not recruitingNCT05152472Phase 2
• An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)Active, not recruitingNCT05112965Phase 3
• Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular CarcinomaWithdrawnNCT05109052Phase 1/2
• Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.Active, not recruitingNCT05097911Phase 1
• SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular CarcinomaTerminatedNCT05093608Phase 1
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersActive, not recruitingNCT05063552Phase 2/3
• Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCCCompletedNCT05053737Phase 1
• Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract CancerCompletedNCT05052099Phase 1/2
• A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05047250Phase 3
• Atezolizumab and Cabozantinib for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05039281Phase 1/2
• Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).Status unknownNCT05038657Phase 2
• Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung CancerStatus unknownNCT05034055Phase 2
• Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLCWithdrawnNCT05007769Phase 2
• Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT05007613Phase 2
• Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung CancerWithdrawnNCT04989283Phase 2
• Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapyActive, not recruitingNCT04962126Phase 2
• Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLCActive, not recruitingNCT04958811Phase 2
• Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHNCompletedNCT04939480Phase 2
• A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)TerminatedNCT04933227Phase 2
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2
• All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerCompletedNCT04919369Phase 1
• Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid TumorsCompletedNCT04896697Phase 1/2
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyActive, not recruitingNCT04873362Phase 3
• SBRT + Atezolizumab + Bevacizumab in Resectable HCCActive, not recruitingNCT04857684Early Phase 1
• A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid TumorsCompletedNCT04857138Phase 1
• A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated GliomasActive, not recruitingNCT04808245Phase 1
• Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
• A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabActive, not recruitingNCT04770896Phase 3
• Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast CancerActive, not recruitingNCT04759248Phase 2
• Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)CompletedNCT04739202Phase 2
• A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast CancerCompletedNCT04732598Phase 3
• Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung CancerCompletedNCT04730999Phase 2
• Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II TrialActive, not recruitingNCT04727307Phase 2
• Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver CancerActive, not recruitingNCT04721132Phase 2
• A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Phase 3
• Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer PatientsStatus unknownNCT04696939Phase 2
• Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBCActive, not recruitingNCT04630730Phase 2
• Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsityWithdrawnNCT04630210Early Phase 1
• Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial CancerCompletedNCT04624399Phase 2
• Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT04622228Phase 2
• A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung CancerWithdrawnNCT04611776Phase 2
• The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
• Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingNCT04589845Phase 2
• A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast CancerCompletedNCT04584112Phase 1
• LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung CancerActive, not recruitingNCT04560972Phase 1
• CRAFT: The NCT-PMO-1602 Phase II TrialCompletedNCT04551521Phase 2
• Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLCTerminatedNCT04549428Phase 2
• A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Phase 3
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Active, not recruitingNCT04524871Phase 1/2
• Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian CancerWithdrawnNCT04510584Phase 2
• Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung CancerCompletedNCT04487756Phase 1/2
• SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph IICompletedNCT04480372Phase 2
• A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)Active, not recruitingNCT04471727Phase 1/2
• A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid TumorsActive, not recruitingNCT04440735Phase 1/2
• A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung CancerTerminatedNCT04432207Phase 1
• First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBCCompletedNCT04408118Phase 2
• Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical CancerCompletedNCT04405349Phase 2
• A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).TerminatedNCT04404140Phase 1
• Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingNCT04387084Phase 1
• A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic MelanomaActive, not recruitingNCT04356729Phase 2
• A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic CarcinomaCompletedNCT04321330Phase 2
• Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer PatientsActive, not recruitingNCT04310020Phase 2
• A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid TumorsTerminatedNCT04303858Phase 1
• Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr CancerActive, not recruitingNCT04289779Phase 2
• Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid TumorsTerminatedNCT04276376Phase 2
• Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate CancerWithdrawnNCT04272645Phase 2
• An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT04250155Phase 1
• Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast CancerWithdrawnNCT04249167Early Phase 1
• Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-EtoposideCompletedNCT04221529Phase 2
• MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue SarcomaCompletedNCT04216953Phase 1/2
• BDB001-102: Open Label Dose Escalation of BDB001 in Combination w AtezolizumabCompletedNCT04196530Phase 1
• A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)CompletedNCT04194203Phase 3
• Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncerActive, not recruitingNCT04186013Phase 2
• A MolEcularly Guided Anti-Cancer Drug Off-Label TrialActive, not recruitingNCT04185831Phase 2
• Atezolizumab Plus Bevacizumab With HCC and HBV InfectionActive, not recruitingNCT04180072Not applicable
• WaKING: Wnt and checKpoint INhibition in Gastric CancerActive, not recruitingNCT04166721Phase 1/2
• Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With SurgeryActive, not recruitingNCT04161755Phase 1
• A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.CompletedNCT04147351Phase 2
• Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical CystectomyActive, not recruitingNCT04138628Phase 2
• Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)Active, not recruitingNCT04134000Phase 1
• Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid TumorsCompletedNCT04096638Phase 1
• Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid TumorsCompletedNCT04084951Phase 1
• ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmationActive, not recruitingNCT04082897Phase 2
• Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]CompletedNCT04059887Phase 4

← Atezolizumab overview